Tesamorelin — Synthetic GHRH Analogue
- HPLC ≥ 98% verified purity
- Lot-specific Certificate of Analysis
- 24-hour nationwide UAE delivery
- Cash on delivery (COD)
- Free shipping over AED 700
- Cold-chain protected shipping
About Tesamorelin
A 44-amino-acid stabilised analogue of growth hormone-releasing hormone — extensively studied for visceral adipose tissue reduction.
Tesamorelin is a synthetic 44-amino-acid peptide — a stabilised analogue of human growth hormone-releasing hormone (GHRH). It carries a trans-3-hexenoyl modification at the N-terminus, which dramatically extends its half-life compared to native GHRH while preserving full receptor agonist activity.
Tesamorelin (developed by Theratechnologies, marketed pharmaceutically as Egrifta) is one of the few GHRH-class peptides to complete formal clinical trial programmes — providing a strong foundation of pharmacology data that makes it a popular target for research models of growth-hormone axis function and visceral adipose tissue (VAT).
Research mechanism
Tesamorelin's mechanism in research is well-characterised:
- Acts on pituitary GHRH receptors, stimulating pulsatile endogenous growth-hormone release
- Increases IGF-1 downstream as the liver responds to elevated GH
- Specifically targets visceral adipose tissue (VAT) — the deep belly fat — in clinical research populations
- Preserves natural circadian GH pulsatility (unlike exogenous GH administration)
- Improves lipid profile and reduces triglycerides in published clinical trial data
Tesamorelin vs other GH-axis research peptides
Tesamorelin is one of several peptides studied as growth-hormone or GHRH axis tools. Below is how it compares mechanistically to the most common alternatives.
| Peptide | Class | Mechanism | Half-life / Profile |
|---|---|---|---|
| Tesamorelin | GHRH analogue (44 aa, modified) | Stabilised GHRH agonist; pulsatile endogenous GH release | ~26 min — stabilised vs native GHRH (~7 min) |
| Sermorelin | GHRH analogue (29 aa) | Native GHRH 1-29 fragment; pulsatile endogenous GH release | ~10-20 min, short-acting |
| CJC-1295 (DAC) | GHRH analogue + DAC | Long-acting GHRH agonist via albumin binding | ~6-8 day half-life — sustained release |
| Ipamorelin | Ghrelin mimetic / GHRP | GHS-R1a agonist (different receptor — selective GH release) | ~2 h, often stacked with GHRH peptides for synergy |
| MK-677 / Ibutamoren | Oral ghrelin mimetic (non-peptide) | GHS-R1a agonist; sustained 24h GH/IGF-1 elevation | Oral, long-acting |
For a full comparison of Tesamorelin against the other leading GHRH analogues — mechanism, half-life, and clinical trial data — read: Tesamorelin vs Sermorelin vs CJC-1295: GHRH Research Peptide Comparison
Common companion peptides for Tesamorelin research
In our customer protocols, Tesamorelin is most often paired with:
Research applications
- Visceral adipose tissue (VAT) research
- Growth-hormone axis and IGF-1 studies
- Body composition and lean mass research
- Lipid metabolism and triglyceride research
- Sleep quality and SWS research
- Anti-aging and somatopause research
Product specifications
Selected research references
- Falutz J et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients With Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
- Stanley TL et al. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014;312(4):380-389.
- Stanley TL et al. Effects of Tesamorelin on Inflammatory and Glycemic Pathways in HIV-Infected Patients. AIDS. 2019;33(15):2367-2374.
- Falutz J et al. Long-term Safety and Effects of Tesamorelin on Visceral Adipose Tissue and Liver Fat. JAMA. 2014 follow-up data.
Frequently asked questions
What's the difference between the 5 mg and 10 mg Tesamorelin vials?
Same peptide, same purity (≥ 98.5%), different total quantity per vial. The 10 mg is our flagship size and offers better value per mg for ongoing research protocols. Both ship with lot-specific COA.
How is Tesamorelin supplied?
REVIVE Tesamorelin is supplied as a white lyophilized powder, HPLC ≥ 98.5% purity, with a lot-level Certificate of Analysis. Store at −20°C, desiccated, protect from light.
How do I reconstitute Tesamorelin?
For the 10 mg vial, add 3–5 mL of bacteriostatic water along the vial wall. Swirl gently — do not shake (peptide chains can shear). Refrigerate at 2–8°C after reconstitution.
Do you ship Tesamorelin across UAE?
Yes — 24h delivery to all 7 emirates with cold-chain shipping for stability. AED 40 standard delivery, free over AED 700. Cash on delivery.
Order Tesamorelin in the UAE today
24-hour delivery to all 7 emirates · Cash on delivery · Free shipping over AED 700
Add to cart WhatsApp inquiry